<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399059</url>
  </required_header>
  <id_info>
    <org_study_id>HURJ2015-01</org_study_id>
    <nct_id>NCT02399059</nct_id>
  </id_info>
  <brief_title>Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution &amp; Oncologic Outcome</brief_title>
  <official_title>Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution During Elective Colorectal Cancer Surgery on the Oncologic Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Elche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads
      to an immunocompromised situation, leaving unattended the neoplasm. It has been described
      that SSI may result in a worse oncologic outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotics combined with lavage have demonstrated a reduction in the bacterial contamination
      and decreases SSI infection rate. SSI leads to an immunocompromised situation, as immunologic
      defense is focused on controlling the septic focus, leaving unattended the neoplasm. It has
      been described that SSI may result in a worse oncologic outcome. The aim of this study is to
      evaluate prospectively the effect of peritoneal lavage with clindamycin and gentamicin on the
      oncologic outcome of colorectal tumours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global survival</measure>
    <time_frame>36 months after intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>36 months after intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Colorectal Tumors</condition>
  <arm_group>
    <arm_group_label>Antibiotic lavage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peritoneal irrigation with Gentamycin - clndamycin solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline lavage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peritoneal irrigation with normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Antibiotic lavage</intervention_name>
    <description>Peritoneal irrigation with gentamycin-clindamycin solution</description>
    <arm_group_label>Antibiotic lavage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal saline lavage</intervention_name>
    <description>Peritoneal irrigation with normal saline</description>
    <arm_group_label>Normal saline lavage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of colon neoplasms

          -  plans to undergo an elective surgery with curative aims

        Exclusion Criteria:

          -  preoperative diagnosis of chronic renal failure (because of the risk of nephrotoxicity
             associated with intraperitoneal gentamicin absorption)

          -  allergy to gentamicin or clindamycin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Ruiz-Tovar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Rey Juan Carlos</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Elche</investigator_affiliation>
    <investigator_full_name>Jaime Ruiz-Tovar, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

